Changes to our company portfolio – MSD and Organon & Co. read more

Changes to our company portfolio

Please note that as of June 3rd 2021, MSD completed the spin-off of products from its women’s health, legacy brands, and biosimilars franchises into the new independent, publicly traded company Organon & Co.

For information on former MSD products now transferred to Organon & Co. please visit their website.

Addressing antibiotic resistance is more critical than ever.
Here’s why.

Since their development, antibiotics have transformed healthcare and saved countless lives globally. But rising levels of antimicrobial resistance (AMR) make current antibiotics less effective. There’s no single or simple solution to the complex problem of AMR, but we’re committed to investing our expertise and resources alongside our partners to get much-needed antibiotics to those who need them most. Lives are at risk, and the time to act is now.

True to our company’s longstanding tradition of preventing and treating infectious diseases, we’re proud to commit to invest $100 million over 10 years in the new AMR Action Fund. Through this ground-breaking partnership of leading pharmaceutical companies, philanthropies, development banks and multilateral organisations, we aim to bridge the gap between the innovative early antibiotic pipeline and patients. New antibiotics are urgently needed. With this new fund for antibiotic research and development, our collective aim is to bring two to four new antibiotics to patients and clinicians by the end of the decade.

Here are five key reasons to build on these collaborative efforts to address AMR:

1. New antibiotics are urgently needed; however, there are relatively few in development
2. Once new antibiotics are approved, they need to be used appropriately
3. We must track resistance trends and use the data to inform on prescribing
4. We need to think beyond human health
5. The time to act against AMR is now

Job code: GB-NON-02954Date of preparation: July 2020